Betta Pharmaceuticals Company Description

Betta Pharmaceuticals Co., Ltd. researches and develops, manufactures, and markets medicines for the treatment of cancer in China.

The company offers Icotinib hydrochloride, an oral epidermal growth factor receptor tyrosine kinase inhibitor, which is used to treat first-line treatment of locally advanced or non-small-cell lung cancer; and Ensartinib hydrochloride, an anaplastic lymphoma kinase inhibitor for the treatment of non-small cell lung cancer.

The company was founded in 2003 and is based in Hangzhou, China.

Betta Pharmaceuticals Co., Ltd.

Country	China
Founded	2003
Industry	Drug Manufacturers - Specialty & Generic
Sector	Healthcare
Employees	1,961
CEO	Lieming Ding

Contact Details

Address: No. 355, Xingzhong Road Hangzhou, 311100 China
Phone	86 57 1892 65665
Website	bettapharma.com

Stock Details

Ticker Symbol	300558
Exchange	Shenzhen Stock Exchange
Fiscal Year	January - December
Reporting Currency	CNY
ISIN Number	CNE100002DD9
SIC Code	2834

Key Executives

Name	Position
Dr. Lieming Ding	Founder, Chairman of the Board, Chief Executive Officer and GM
Jianxun Fan	Vice President, Chief Financial Officer and Director
Jiang Wan	Senior Vice President, Chief Operating Officer and Director
Jia Tong	Chief Administrative Officer and Director
Dr. Mao Li	President of Research & Development and Chief Medical Officer
Lingxi Wu	Board Secretary and Head of Chairman Office
Yangnan Zhang	Chairman of the Supervisory Board and Senior Director of Project Declaration
Fei Wu	Supervisor and Senior Director of Internal Control Affairs